Abevmy Market Report 2025: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

This Abevmy market report delivers an in-depth analysis of the market’s key characteristics, including size, growth potential, and segmentation. It provides a detailed breakdown of the market across major regions and leading countries, highlighting historical data and future growth projections. The report also examines the competitive landscape, market share insights, emerging trends, and strategic developments shaping the market.

Market growth during the historic period can be attributed to several factors, including the rising global prevalence of cancer, increasing adoption of biosimilars in oncology treatments, growing demand for cost-effective cancer therapies, expanding approval of biosimilars for multiple oncology indications, and favorable regulatory policies that support the adoption of biosimilars.

Growth during the market's forecast period can be attributed to factors such as rising healthcare expenditure in emerging markets, increasing awareness about biosimilars among healthcare providers, a growing geriatric population with higher cancer susceptibility, the expansion of healthcare infrastructure in developing countries, and government initiatives promoting biosimilar usage. Key trends expected to shape the forecast period include product innovation, strategic partnerships, technological advancements, and growing investments in biosimilar research and development.

The growing prevalence of cancer is anticipated to drive the expansion of the abevmy market. Cancer incidence is influenced by several factors, including aging populations, lifestyle choices such as poor diet, physical inactivity, smoking, and alcohol use, as well as environmental exposures to carcinogens. The rising cancer rates can be attributed to these factors. For example, in January 2023, the American Cancer Society reported a significant increase in cancer cases in the United States, with 1,958,310 new cases in 2023, marking a 3.16% rise from 1,898,160 cases in 2021. As the prevalence of cancer continues to climb, the demand for treatments like abevmy is expected to increase.

A key trend shaping the Abevmy market is the growing emphasis on developing biosimilars to improve access to affordable biologic therapies, address unmet medical needs, and reduce healthcare costs. Biosimilars are designed to offer cost-effective alternatives to originator biologics, while ensuring comparable efficacy, safety, and quality. For instance, in May 2022, Viatris and Biocon Biologics launched Abevmy (bevacizumab), a biosimilar to Roche’s Avastin, in Canada. Health Canada approved Abevmy for use in four oncology indications. Abevmy functions by inhibiting vascular endothelial growth factor (VEGF), a protein responsible for blood vessel formation. By blocking VEGF, Abevmy reduces angiogenesis, which deprives tumors of the oxygen and nutrients they need to grow and spread.

In November 2022, Biocon Biologics Ltd., an India-based subsidiary of Biocon Ltd. specializing in biopharmaceuticals, acquired the global biosimilars business of Viatris Inc. for an undisclosed amount. This acquisition is intended to reinforce Biocon Biologics' position in the growing biosimilars market. Viatris Inc., a US-based pharmaceutical and healthcare company, focuses on medicines across major therapeutic areas, including cancer treatments such as Bevacizumab.

Major players operating in the abevmy market are Biocon Biologics Ltd., Viatris Inc.

North America was the largest region in the abevmy market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in abevmy report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa. The countries covered in the abevmy market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Abevmy is a biosimilar version of the cancer drug bevacizumab, developed to provide a more affordable alternative while maintaining similar efficacy and safety. It works by targeting vascular endothelial growth factor (VEGF), a protein responsible for the formation of blood vessels that supply tumors with oxygen and nutrients. By inhibiting VEGF, Abevmy helps prevent the growth of new blood vessels (angiogenesis), thereby limiting tumor growth and spread.

The main dosages of abevmy available in the market are 100mg and 400mg. The 100mg dose is specifically formulated for patients requiring treatment for various cancers. Abevmy is used to treat cancer and eye diseases and is distributed through channels such as direct tenders, hospital pharmacies, retail pharmacies, and online pharmacies. The end users include hospitals, cancer support centers, academic and research institutes, and home healthcare providers.

The abevmy market research report is one of a series of new reports that provides abevmy market statistics, including abevmy industry global market size, regional shares, competitors with a abevmy market share, detailed abevmy market segments, market trends, and opportunities, and any further data you may need to thrive in the abevmy industry. This abevmy market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The abevmy market consists of sales of intravenous (IV) infusion. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 3-5 business days.